Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients

    December 2022 in “ Viruses ”
    Efstathios S. Giotis, Emine Çil, Greg N. Brooke
    Studysummary This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. COVID-19: Pulmonary and Extra Pulmonary Manifestations Frontiers in Public Health · 2021
    2. The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells Nature Communications · 2021
    3. Do Anti-Androgens Have Potential as Therapeutics for COVID-19? Endocrinology · 2021
    4. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    5. Sex Differences in SARS-CoV-2 Infection Rates and the Potential Link to Prostate Cancer Communications biology · 2020
    6. Revising the Role of the Androgen Receptor in Breast Cancer Journal of Molecular Endocrinology · 2014
    7. Visualizing Androgen Receptor Activity in Male and Female Mice PloS one · 2013
    8. Antiandrogen Therapy for Androgenetic Alopecia Expert Review of Dermatology · 2006